Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Volume and Donepezil Response in Alzheimer's
NCT00165750Phase 4Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donepezil in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoints: Regional Brain Volume measured by MRI at 24 weeks and Alzheimer's Disease Assessment Scale - Cognitive Subscale at 24 weeks. Started Mar 2005; status: terminated.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00165750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165750.